This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mastercard (MA) Ties Up for Virtual Card Uptake in Travel Space
by Zacks Equity Research
Mastercard (MA) joins forces with Sabre and Conferma Pay to facilitate payments in the travel ecosystem. MA also decides to buy a minority stake in Conferma Pay.
Franklin Covey Company (FC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Franklin Covey (FC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Exponent (EXPO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 11.90% and 1%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Mastercard (MA) Adds Experts to Client Services Team in Egypt
by Zacks Equity Research
Mastercard (MA) inflates the base of its Advisors Client Services Hub in Egypt by expanding the panel of experts at the site. This will boost MA to serve its global clients with professional ease.
Exponent (EXPO) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 8.89% and 0.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for Exponent (EXPO)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Exponent (EXPO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Exponent (EXPO) is Poised for a Turnaround After Losing 19.9% in 4 Weeks
by Zacks Equity Research
Exponent (EXPO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Exponent (EXPO) is Poised for a Turnaround After Losing 16.5% in 4 Weeks
by Zacks Equity Research
Exponent (EXPO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Exponent (EXPO) is Poised for a Turnaround After Losing 14.6% in 4 Weeks
by Zacks Equity Research
Exponent (EXPO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Exponent (EXPO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 7.69% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 4th
by Zacks Equity Research
AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
Exponent (EXPO) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 5.56% and 2.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exponent (EXPO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Franklin Covey (FC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Franklin Covey (FC) delivered earnings and revenue surprises of 800% and 10.64%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 15.00% and 3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FTI Consulting (FCN) Appoints New Senior Managing Director
by Zacks Equity Research
FTI Consulting (FCN) welcomes Jim Wrynn to the position of senior managing director in its Global Insurance Services practice.
Exponent (EXPO): Strong Industry, Solid Earnings Estimate Revisions
by Aditi Saraogi
Exponent (EXPO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Are You Looking for a Top Momentum Pick? Why Exponent (EXPO) is a Great Choice
by Zacks Equity Research
Does Exponent (EXPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Exponent (EXPO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exponent (EXPO) delivered earnings and revenue surprises of 14.29% and 6.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Exponent (EXPO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Exponent (EXPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tetra Tech (TTEK) Buys Kaizen, Expands International Footprint
by Zacks Equity Research
Tetra Tech's (TTEK) acquisition of Kaizen will enable it to boost its capabilities in international development management consulting services for its customers.
Exponent (EXPO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Exponent (EXPO) has been struggling lately, but the selling pressure may be coming to an end soon
Equifax (EFX) Rides on Product Strength, Debt Woes Stay
by Zacks Equity Research
Equifax (EFX) is benefiting from a solid product portfolio and clear understanding of the diverse sectors it serves.